MateuszOpyrchalMDPhD
Oncology • Indianapolis, INBreast Cancer, Hematologic Oncology
Associate Professor of Medicine; Medical Oncology Indiana University, Indianapolis IN
Dr. Opyrchal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1030 W Michigan St
Indianapolis, IN 46202Phone+1 888-600-4822
Summary
- Dr. Mateusz Opyrchal is an oncologist in Indianapolis IN and is affiliated with Simon Cancer Center. He received his medical degree from Rutgers New Jersey Medical School and has been in practice 10 years. He also speaks multiple languages, including Polish. He specializes in breast cancer and experimental theuraputics and is experienced in immunotherapy, cellular therapy, breast cancer, melanoma, and combined modality therapy.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2010 - 2013- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2007 - 2010
Rutgers New Jersey Medical SchoolClass of 2007
Certifications & Licensure
IN State Medical License 2021 - 2025
IL State Medical License 2019 - 2023
MO State Medical License 2019 - 2022
NY State Medical License 2013 - 2021
MN State Medical License 2008 - 2014
Awards, Honors, & Recognition
- Golden Apple Teaching Award 2016
- Promising Young Investigator Award University of Buffalo Medicine Department, 2015
Clinical Trials
- Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer Start of enrollment: 2018 Feb 19
- T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer Start of enrollment: 2018 Dec 06
- Evaluate Eribulin ORA in Subjects With Solid Tumors Start of enrollment: 2019 Jul 29
Publications & Presentations
PubMed
- A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors.Aurora Norman, Mahesh Seetharam, Jacob Allred, Jianping Kong, Mateusz Opyrchal
BJC Reports. 2025-01-14 - Inhibition of Glutamate-to-Glutathione Flux Promotes Tumor Antigen Presentation in Colorectal Cancer Cells.Tao Yu, Kevin Van der Jeught, Haiqi Zhu, Zhuolong Zhou, Samantha Sharma
Advanced Science. 2025-01-01 - Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer.Shipra Gandhi, Ronald T Slomba, Cayla Janes, Victoria Fitzpatrick, Janine Miller
Journal for Immunotherapy of Cancer. 2024-11-14
Press Mentions
April 20 - Vera Bradley Foundation for Breast Cancer Donates $12.5M to the Indiana University School of MedicineApril 20th, 2022
Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-Oncology ProgramJune 17th, 2019
New Clinical Trials at Roswell Park Build on Virus Research for Innovative Immunotherapy ApproachJanuary 3rd, 2019- Join now to see all
Grant Support
- Predictive Markers of Response in Ph II Axitinib in MelanomaNCCN/Pfizer (PI)2011–2018
Committees
- Member, Medication Orders Subcommittee 2018 - 2019
- Member, Health Informatics Committee 2018 - 2019
- Member, IND SAE Trending Committee 2017 - 2019
- Member, Clinical Research IT Governance Committee 2017 - 2019
- Member, Chief of Off-Label Committee 2017 - 2019
- Member, GYN Molecular Tumor Path Conference 2016 - 2019
- Member, Scientific Advisory Committee (SAC) 2016 - 2019
- Member, Pharmacy & Therapeutic Committee (P & T) 2015 - 2019
- Member, Scientific Review Committee (SRC) 2014 - 2019
Professional Memberships
- American Association for Cancer Research (AACR)Member
- Member
- Member
Other Languages
- Polish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
